Free Trial

Acrivon Therapeutics (ACRV) Competitors

Acrivon Therapeutics logo
$2.04 +0.12 (+6.25%)
Closing price 04:00 PM Eastern
Extended Trading
$2.03 -0.01 (-0.54%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACRV vs. FHTX, TRDA, CLLS, GNLX, GNFT, TARA, ZURA, MDWD, PYXS, and EPRX

Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Foghorn Therapeutics (FHTX), Entrada Therapeutics (TRDA), Cellectis (CLLS), Genelux (GNLX), GENFIT (GNFT), Protara Therapeutics (TARA), Zura Bio (ZURA), MediWound (MDWD), Pyxis Oncology (PYXS), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.

Acrivon Therapeutics vs. Its Competitors

Foghorn Therapeutics (NASDAQ:FHTX) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acrivon Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics-311.90% N/A -28.00%
Acrivon Therapeutics N/A -50.78%-46.08%

Foghorn Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 170.27%. Acrivon Therapeutics has a consensus target price of $15.00, indicating a potential upside of 635.29%. Given Acrivon Therapeutics' higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Foghorn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.00
Acrivon Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Foghorn Therapeutics has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Acrivon Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$22.60M10.18-$86.62M-$1.19-3.42
Acrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.91

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 0 mentions for Acrivon Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.05 beat Acrivon Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Foghorn Therapeutics Neutral
Acrivon Therapeutics Neutral

Summary

Foghorn Therapeutics beats Acrivon Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRV vs. The Competition

MetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$64.17M$2.62B$6.11B$10.62B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-0.9123.5929.2227.30
Price / SalesN/A587.20491.48184.03
Price / CashN/A27.2425.8230.35
Price / Book0.365.4112.476.65
Net Income-$80.56M$33.06M$3.32B$276.14M
7 Day Performance17.24%1.33%1.87%0.01%
1 Month Performance25.15%10.15%8.40%3.60%
1 Year Performance-74.66%-2.20%63.49%32.76%

Acrivon Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRV
Acrivon Therapeutics
2.5958 of 5 stars
$2.04
+6.3%
$15.00
+635.3%
-76.7%$64.17MN/A-0.9158Positive News
FHTX
Foghorn Therapeutics
2.5433 of 5 stars
$4.04
+1.3%
$11.00
+172.3%
-47.3%$225.55M$22.60M-3.39120Gap Up
TRDA
Entrada Therapeutics
2.9027 of 5 stars
$6.25
+6.5%
$25.67
+310.7%
-64.2%$223.28M$79.48M-3.51110
CLLS
Cellectis
2.1789 of 5 stars
$3.95
-0.8%
$6.00
+51.9%
+107.9%$221.22M$49.22M-4.82290Analyst Forecast
Gap Down
GNLX
Genelux
1.0966 of 5 stars
$6.51
+13.8%
$20.33
+212.3%
+136.7%$216.06MN/A-7.5710News Coverage
Analyst Forecast
Gap Up
High Trading Volume
GNFT
GENFIT
1.8155 of 5 stars
$4.08
-3.8%
$7.00
+71.6%
-31.3%$212.01M$76.77M0.00120Positive News
TARA
Protara Therapeutics
1.7592 of 5 stars
$5.56
+1.3%
$19.60
+252.5%
+191.1%$211.81MN/A-3.4330
ZURA
Zura Bio
3.0393 of 5 stars
$3.37
+5.0%
$11.60
+244.2%
-31.5%$208.71MN/A-4.813Short Interest ↑
MDWD
MediWound
1.8959 of 5 stars
$19.69
+4.7%
$32.25
+63.8%
+12.0%$208.38M$19.86M-7.4680
PYXS
Pyxis Oncology
2.8579 of 5 stars
$3.58
+6.5%
$7.75
+116.5%
-4.5%$208.38M$2.82M-2.2460
EPRX
Eupraxia Pharmaceuticals
2.6317 of 5 stars
$5.88
+1.7%
$11.00
+87.1%
+134.3%$207.85MN/A-6.9229Short Interest ↑

Related Companies and Tools


This page (NASDAQ:ACRV) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners